Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party

Ali Bazarbachi*, Ariane Boumendil, Hervé Finel, Mohamad Mohty, Luca Castagna, Didier Blaise, Karl S. Peggs, Boris Afanasyev, J. L. Diez-Martin, Paolo Corradini, David Michonneau, Stephen Robinson, Gonzalo Gutiérrez García, Francesca Bonifazi, Ibrahim Yakoub-Agha, Zafer Gülbas, Adrian Bloor, Jeremy Delage, Albert Esquirol, Ram MalladiChristof Scheid, Jean El-Cheikh, Hervé Ghesquières, Silvia Montoto, Peter Dreger, Anna Sureda

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

9 Citations (Scopus)

Fingerprint Dive into the research topics of 'Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party'. Together they form a unique fingerprint.

Medicine & Life Sciences